C.M.R. 10, 144, ch. 258, app A
* Category I Diseases must be reported to the Department immediately.
** Category II Diseases must be reported within 48 hours of the diagnosis or laboratory test result.
# Laboratories are to submit isolates or clinical specimens for the following, as well as any isolates or clinical specimens, as requested by HETL for confirmation, typing and/or antibiotic sensitivity.
Table 1.
Notifiable Diseases and Conditions | |||
Disease or Condition | Agent | ||
** | Acquired immunodeficiency syndrome (AIDS) | Human immunodeficiency virus | |
** | Acute flaccid myelitis (AFM)1 | ||
** | Anaplasmosis | Anaplasmaphagocytophilum | |
* | # | Anthrax | Bacillus anthracis |
** | Babesiosis | Babesia microti | |
* | # | Botulism | Clostridium botulinum |
** | Borrelia miyamotoi | Borrelia miyamotoi | |
* | # | Brucellosis | Brucella species |
** | California serogroup viruses | ||
** | Campylobacteriosis | Campylobacter species | |
* | # | Candida auris2 | Candida auris |
* | # | Carbapenemase-producing carbapenem-resistant organisms3 | Enterobacteriaceae spp. Pseudomonas aeruginosa (non-mucoid only) Acinetobacter baumannii |
** | Carbon monoxide poisoning4 | Carbon monoxide | |
** | Chancroid | Haemophilusducreyi | |
** | Chlamydia | Chlamydia trachomatis | |
** | Chickenpox (varicella) | Varicella-zoster virus | |
** | Chikungunya | Chikungunya virus | |
* | # | Coronavirus (novel, MERS, and SARS) | Coronavirus |
** | Creutzfeldt-Jakob disease, < 55 years of age | Creutzfeldt-Jakob agent | |
** | Cryptosporidiosis | Cryptosporidium species | |
** | Cyclosporiasis | Cyclospora | |
** | Dengue | Dengue fever virus | |
Disease or Condition | Agent | ||
* | # | Diphtheria | Corynebacterium diphtheriae |
** | # | E.coli, Shiga toxin-producing (STEC) | Escherichia coli, Shiga toxin-producing |
** | Eastern equine encephalitis | Eastern equine encephalitis virus | |
** | Ehrlichiosis | Ehrlichiaspecies | |
** | Giardiasis | Giardia species | |
** | Gonorrhea | Neisseria gonorrhoeae | |
** | # | Haemophilus influenzae,invasive | Haemophilus influenzae |
** | Hantavirus, pulmonary and non-pulmonary syndromes | Hantavirus | |
** | Hemolytic-uremic syndrome (post-diarrheal) | Escherichia coli, Shiga toxin-producing | |
* | Hepatitis A, B, C, D, E (acute) | Hepatitis A, B, C, D, E viruses | |
** | Hepatitis B, C, D (chronic) | Hepatitis B, C, D viruses | |
** | Human immunodeficiency virus (HIV)5 | Human immunodeficiency virus | |
** | Influenza-associated pediatric death | Influenza virus | |
* | # | Influenza A, novel | Influenza virus |
** | Influenza-associated hospitalizations, laboratory-confirmed | Influenza virus | |
** | Legionellosis | Legionella species | |
** | Leptospirosis | Leptospira species | |
** | # | Listeriosis | Listeria monocytogenes |
** | Lyme disease | Borrelia burgdorferi | |
** | Malaria | Plasmodium species | |
* | # | Measles | Rubeola virus |
* | # | Meningococcal disease, invasive | Neisseria meningitidis |
* | # | Mumps | Mumps virus |
* | Pertussis | Bordetella pertussis | |
* | # | Plague | Yersinia pestis |
* | # | Poliomyelitis | Poliovirus |
** | Powassan | Powassan or deer tick virus | |
** | Psittacosis | Chlamydia psittaci | |
* | Q fever | Coxiella burnetii | |
* | # | Rabies (human and animal) | Rabies virus |
** | Rabies post-exposure prophylaxis | ||
* | # | Ricin poisoning | |
* | # | Rubella (including congenital) | Rubella virus |
** | # | Salmonellosis | Salmonella species |
* | Shellfish poisoning | ||
** | # | Shigellosis | Shigella species |
* | # | Smallpox | Variola virus |
** | Spotted fever rickettsiosis | Rickettsia rickettsii | |
Disease or Condition | Agent | ||
** | St. Louis encephalitis | St. Louis encephalitis virus | |
* | # | Staphylococcus aureus non-susceptible to vancomycin6 | Staphylococcus aureus |
** | Streptococcus group A, invasive | Streptococcus pyogenes (group A beta hemolytic strep) | |
** | Streptococcus pneumoniae, invasive | Streptococcus pneumoniae | |
** | Syphilis | Treponema pallidum | |
* | # | Tetanus | Clostridium tetani |
** | Trichinosis | Trichinella species | |
* | # | Tuberculosis (active and presumptive) | Mycobacterium tuberculosis |
* | # | Tularemia | Francisellatularensis |
** | # | Vibrio species, including cholera | Vibrio species |
** | Vaping-associated pulmonary illness7 | ||
* | Viral hemorrhagic fever | Arenaviruses and others | |
** | West nile | West nile virus | |
** | Western equine encephalitis | Western equine encephalitis virus | |
** | Yellow fever | Yellow fever virus | |
** | Zika virus disease | Zika virus | |
* | Any case of unusual illness of infectious cause | ||
* | Any cluster/outbreak of illness with potential public health significance | ||
1 An illness with an onset of acute focal limb weakness and either 1) cerebrospinal fluid with an elevated white blood cell count or 2) a magnetic resonance image (MRI) showing a spinal cord lesion largely restricted to gray matter and spanning one or more spinal segments.
2 Detection of Candida auris in a specimen using culture or culture independent diagnostic test; or detection of an organism that commonly represents a Candida auris misidentification.
3 Carbapenemase-producing carbapenem-resistant organisms are:
* Carbapenem-resistant organisms, as defined by the Clinical Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing M100 (http://www.clsi-m100.com), that test positive for Carbapenemase-producing by a phenotype method or for a known carbapenemase resistance mechanisms by a recognized test, as defined by the U.S. Centers for Disease Control and Prevention (https://wwwn.cdc.gov/nndss/conditions/carbapenemase-producing-carbapenem-resistant-enterobacteriaceae/case-definition/2018/).
* Reporting will include test method used, result, and where applicable, specific resistance mechanisms identified.
* Isolate submission is required for all carbapenem-producing carbapenem-resistant organisms. If phenotypic or resistance mechanism test results are not available for a carbapenem-resistant organism, then isolate submission of the carbapenem-resistant organism is required to determine carbapenemase-producing status.
4 All cases with clinical signs, symptoms or known exposure consistent with diagnosis of carbon monoxide poisoning, and/or: a carboxyhemoglobin (COHb) level equal to or above 5%.
5Any human immunodeficiency virus (HIV) test results, including:
* All reactive/repeatedly reactive initial HIV immunoassay results and all results (e.g. positive, negative, indeterminate) from all supplemental HIV immunoassays (HIV-1/2 antibody differentiation assay, HIV-1 Western blot, HIV-2 Western blot or HIV-1 Immunofluorescent assay);
* All HIV nucleic acid (RNA or DNA) detection tests (qualitative and quantitative), including tests on individual specimens for confirmation of nucleic acid amplification testing (NAAT) screening results;
* All CD4 lymphocyte counts and percentages, unless known to be ordered for a condition other than HIV;
* HIV genotypic resistance testing, nucleotide sequence results; and,
* Positive HIV detection tests (including, but not limited to culture, P24 antigen).
6 As defined by the most current Clinical Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing M100 (http://www.clsi-m100.com).
7 Clinicians should report cases with onset on or after May 1, 2019, that meet the criteria of (1) a significant respiratory illness of unclear etiology and (2) a history of vaping.
C.M.R. 10, 144, ch. 258, app A